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Hypertrophic cardiomyopathy is a primary cardiac disease 
characterized by a vast clinical and morphologic spectrum (1). 
Some patients develop disabling symptoms of exertional dys- 
pnea, fatigue and chest pain unresponsive to pharmacologic 
agents. Functional impairment may result from a number of 
pathophysiologic mechanisms, most frequently involving left 
ventricular diastolic dysfunction, but also myocardial ischemia, 
arrhythmias and dynamic obstruction to left ventricular out- 
flow (1,2). 
Histories! perspectives. Recently, there has been interest in 
the application of pacing technology to those patients with 
hypertrophic cardiomyopathy demonstrating marked outflow 
obstruction and severe drug-refractory symptoms of heart 
failure (3-5). Pacing has been advocated as a possible altema- 
tive to surgical intervention (ventricular septal myotomy- 
myectomy or mitral valve replacement), which at present 
represents the standard treatment approach for such patients 
(1,2). This therapeutic concept was first proposed in the 1970s 
in Germany (6) and subsequently in France (7). Subsequently, 
in 1988, McDonald et al. (8) descriid symptomatic benefit 
associated with permanent dual-chamber pacing in 11 patients. 
Four years later, Swiss investigators (3) demonstrated partial 
reduction in basal outflow gradient with temporary and per- 
manent pacing, as well as subjecGve improvement in symp 
toms. Subsequently, a report ?f 84 patients (4) attributed 
multiple benefits to dual-chamber pacing, induding a marked 
symptomatic improvement in virtually all patients, associated 
with striking reduction in gradient and a striking decrease in 
left ventricular mass over a brief follow-up period of 2 years. It 
should be emphasized that these previous reports (3,4) largely 
reflect a subjective improvement in symptoms outside the 
context of controlled or randomized study designs. Indeed, 
objective testing of exercise capacity before and after pace- 
maker implantation in hypertrophic cardiomyopathy has dem- 
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onstrated only modest prolongation of exercise time. a finding 
seemingly inconsistent with the magnitude of subjective im- 
provement reported (4,9). Finally, recent preliminary reports 
have demonstrated more highly variable patient responses to 
pacing and are much more restrained in their advocacy of this 
treatment in patients with hypertrophic cardiomyopathy (lo- 
14). 
Must recent observations. In this issue of the Journal, 
Nishimura et al. (15) at the Mayo Clinic other an important 
perspective on this controversy ~ by critically examining the 
effects of dual-chamber pacing on left ventricular systolic and 
diastolic function in 29 patients with hypertrophic cardiomy- 
opathy. These investigators prospectively studied the acute 
hemodynamic effects of P-synchronous pacing at cardiac cath- 
eterization by combining high fidelity pressure recordings and 
pulsed Doppler transmitral flow-velocity measurements. 
Transseptal catheterization avoided catheter entrapment and 
ensured more accurate measurement of left ventricular sy&L 
pressure from the inflow portion of the chamber (2). 
Within their study design, the authors were able to show 
hemodynamic deterioration in several key variables as a con- 
sequence of pacing. With respect to diastolic function, a 
significant increase in both the time constant of ventricular 
relaxation and left atrial pressure were identified during pacing 
compared with that during periods of sinus rhythm, contrary to 
a previous suggestion tnat pacing may benefit patients with 
hypertrophic cardiomyopathy by enhancing diastolic function 
(9). In terms of systolic performance, pacing-related decreases 
in cardiac output and peak positive dP/dt were demonstrable. 
Each of these bemodynarnic alterations was evident at the 
optimal atrioventricuiar (AV) delay (defined as the longest 
interval with maximal pre-excitation, i.e., full ventricular acti- 
vation by the pacemaker), but were of even greater magnitude 
at the shortest delay of 60 ms, an interval within the range used 
in some previous studies (3,8,9). 
Of note, Niihimura et al. found only a modest decrease 
(-15%) in the left ventricular outflow tract gradient with 
temporary dual-chamber pacing at optimal AV delay, contrast- 
ing sharply with the more substantial reductions in gradiint 
reported in previous studies (4,9), and far more modest than 
the normalization of intraventricular pressures routinely 
achieved with operation in thii disease (1,2,13,16). Further- 
more, this response of the gradient to pacing proved to be 
nonuniform, with some in&dual patients showing no w 
or even an increase in outflow obstm&n. It is possible that 
previous studies, in whii transseptal catheterization and high 
lidetity catheters were not used, may have overestimated the 
magnitude of left venbiadar systolic pressure due to the 
phenomenon of cavity obliteration. Therefore, Nishimura et al. 
(IS) have appropriately addressed a number of issues, in&d- 
ing the critical consideration of safety, by eU@asii that 
pacing therapy in severely symptomatic patients with obsbuc- 
tive hypertropbic cardiomyopathy is not necessarity innoQnt 
andmayimposeahemodynamicburdenwithputentiaUy 
dekteticonseqwnces 
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It should also be noted that the observations of Nishimura 
et al. (15) were made in the cardiac catheterization laboratory 
under controlled conditions. Consequently, as the authors 
themselves concede, some uncertainty persists regarding the 
extent to which the hemodynamic effects of dual-chamber 
pacing observed in such a laboratory setting can be extrapo- 
lated to clinical circumstances encountered with permanent 
pacemaker implantation. On the other hand, acute hemody- 
namic studies, such as those described by Nishimura et al., may 
be useful as screening procedures from which to judge the 
prudence of permanent pacemaker implantation in patients 
with evidence ,of impaired left ventricular performance during 
tempomy pacing. 
Current perspectives. It is also worthwhile to emphasize, in 
the interest of perspective, that the ongoing debate over pacing 
in hypertrophic cardiomyopathy is, in reality, focused on a 
relatively small subgroup of patients with this disease--those 
with both marked obstruction to left ventricular outflow and 
severe symptoms of heart failure refractory to drug treatment. 
Indeed, it is estimated that this subset of patients probably 
comprises only 5% to 10% of the overall patient population 
with this disease (1). 
Dual-chamber pacing should not be perceived as a general 
therapeutic panacea or cure for hypertrophic cardiomyopathy, 
a complex disease characterized by a greatly hypertrophied, 
noncompliant left ventricle as well as substantial clinical and 
patbophysiologic heterogeneity (1,2). For example, at present, 
pacing has no defined role in diminishing risk for sudden 
cardiac death, nor in relieving the symptoms of patients with 
the ~ombstmctive form of the disease (17). On the other 
hand, it is possible that particular subgroups of patients may 
yet be recognized within the broad disease spectrum of hyper- 
trophic cardiomyopathy that could be expected to preferen- 
tially derive symptomatic benefit from pacing. Finally, it should 
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the primary treatment for refractory symptoms. Therefore, it is 
perhaps appropriate to sound this cautionary note regarding 
dual-chamber pacing as a treatment strategy in hypertrophic 
cardiomyopathy until more definitive information becomes 
available from the prospective, well controlled and randomized 
trials currently in progress. Indeed, the present report of 
Nishimura et al. (15) from the Mayo Clinic should serve as an 
important stimulus for much needed studies aimed at &fining 
more precisely the true role of dual-chamber pacing in the 
therapeutic armamentarium of patients with hypertrophic car- 
diomyopathy. 
References 
I. Maron BJ, Bonow RO. Cannon RO III, et al. Hypertqhic cardiimyopathy: 
interrelations of cliiical manifestations pathoph,ysiology, and therapy. 
N Engl J Med 1987;316:780-9,844-U 
2. Wile ED, Sawn Z, Henderson MA, et al. Hypxtrophic cardiomyopathy: 
the importance of the site and extent of hypertrophy-a review. Prog 
Cardiovasc Dis 1985:28:1-83. 
3. leanrenaud X, Gq J-J, Kappcnberger L Et%% of dual-chamber pacing in 
hvuertroohic obstructive cardiomvooathv. Lancet 1992z33~1318-23. 
4. ~~nana&r L Epstein ND, Co&i Ri, et al. kmg-term rcs&, of dual- 
chamber (DDD) pacing in obstructive hypertmpbic cardiomyopathy. Evr- 
dence for progressive symptomatic and hemodynamic improvement and 
reduction of left ventricular hypertropby. Circtdatioa 1994;90:2731-42. 
5. Rishi F, Hok JE. Sharma S, Aold D, Campbell RM. Temporary dual 
chamber pacing in pediatric patients with hypertrophic obstrwtiw cardio- 
myopathy [absbact]. Circulation 199388 Snppl I:1485 
6. Hasenstein P, Starch H-H. Schmitz W. Erfahntngen mit der s&ittmach- 
erdauer behaitdhmg bei patienten mit obsttuktiver kardiomyopathie. [Re- 
sults of electrieai pacing in paknts with obstructive cacdiimyopathy.] 
Thoraxchirorgie 1975;U:4%-8. 
7. Lhtpmt G, Valeix B, Lefewe I, et al. btcre: de la stimulation ventkdaire 
droite permaoente dam la cardiomyopalhie obstructive. Now Press Med 
1978:322868-9. 
8. McDo~d K, MeWilliams E, O’Keefe B, et al. Functional assessment of 
paticnb treated with permanent dual chamber pacing ac a primary treatment 
for hypertrnphi cardiomyopathy. Eur Heart J 1988$893-8. 
9. McDonat:~, Maorer B. Permanent pacing as treatment for hypertropbic 
ca&-rz,.~y+4tn J Cardiol 1991;68:108-10. also be emphasized that pacing therapy in severely symptom- 
atic patients with obstructive hvnertroohic carrlinm~~a:;~ 
cannot necessarily be regarded as m&e and id&d* may 
prove challenging with long-term pacemaker maintenance and 
adjustment of the optimal AV delay often necessary in the 
pursuit of clinical benefit. Patients can require, even after the 
institution of pacing, substantial drug therapy or AV node 
ablation to achieve optimal pacing conditions, thus creating a 
situation in which it becomes diflicult to discern to what extent 
any perceived clinical benefit may actually be attriiutable to 
pacing itself. 
Conelusions. The evolving but limited clinical experience 
with permanent pacing therapy in hypertrophic cardio- 
myopathy suggests the importance at this time of adopting a 
measured approach and prudent restmint ,to the widespread 
at@tion of this potential treatment modality for patients with 
hype- cardiiopathy. It would indeed be shortsighted 
to ignore the time-honored surgical treatment (1,2,13,16) for 
this dii by premature acceptance of permanent pacing as 
obstruaion bt ; Impairs diabolic ftmctioe in hypertrophic &di&yop& 
[abstract]. J Aw Co11 C&did 1994;23:1lA. 
. ,-r?. -5c;occhi S. 10 MA. Pkione F. et al. Atrioventkdar twine relieves 
11. Illii MC, Laveyp TL, Hemigoe AC, et al. lack of leh ventricular mass 
redunion six mon.bhet dual &mber pacing implantation in obsvuctive 
hypertmphic cardiom@pathy [abstixtl. Circulation 1994;W Suppl M-665. 
12. Nishimura RA, Trusty JM. Hayes DL et al. Dual-r pa&g for 
patients w’th hypertrophi carkxnyopxhy: a pmspe&e randot&&, 
double-bk iwvet trial [abstrxt]. J Am toll Cardiol 1995;2s:lOk 
13. Niiimwa ) Danielson GK Dual chamber pacing for hypertwpbic 
ohstrnctive c.m.mmyopa~ Has it, time come? Br Heart J 1993;70-301-3. 
14. Sadd N, Siaoe MB, Siimt JP. c al. Dual cbambcr pacing in refractory 
hypertrophii obsmtctive cardiiyopathy: a twcenter Ewopcan experience 
in 34 consotive pat&t& labs&act]. J Am Coil Cardiol199$;25:233A. 
15. Nishimwa Rk Hayes DL lktmp DM, Holmes DR Jr, Tajii AI. E&t of 
doakhamber pacing on s@olic and diastolic function in patients with 
hypervophic cardiomyopathy: acote Doppler eckcardiogqbic sod catbe- 
terization hcmodywnic study. J Am coil Cwdiol1996~421-30 
16. Mclnmh CL Mm 81. Current operative txemment of I&&UC& byper- 
ttupbc cmtiquptity. Ciilatioo 198&78:487%5. 
17. Cannon RO, Ttipodi D. Di!kiatt V, et al. Resdts of permanent dual. 
chamber pacing in symptomatic -itrypemophi~- 
thy. Am J C&ii 1994;n571-6. 
